Szyman Catherine M. 4
4 · Edwards Lifesciences Corp · Filed May 6, 2024
Insider Transaction Report
Form 4
Szyman Catherine M.
CVP, Critical Care & Vascular
Transactions
- Tax Payment
Common Stock
2024-05-04$85.25/sh−3,442$293,431→ 45,576.437 total - Tax Payment
Common Stock
2024-05-03$85.06/sh−479$40,744→ 43,222.437 total - Exercise/Conversion
Common Stock
2024-05-04+5,796→ 49,018.437 total - Exercise/Conversion
Performance Rights
2024-05-04−5,796→ 0 totalFrom: 2024-05-04Exp: 2028-05-03→ Common Stock (5,796 underlying)
Footnotes (1)
- [F1]On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.